Timothy G. Cameron

Specialty / focus. Timothy G. Cameron is a first-chair commercial trial lawyer whose practice centers on antitrust, securities, shareholder-derivative, M&A, and product-liability disputes, with heavy cross-border work — not core patent litigation (Chambers USA; firm bios). His one tracked patent-adjacent appearance, Regeneron Pharmaceuticals, Inc. v. Amgen Inc. (D. Del., No. 1:22-cv-00697), is in substance an antitrust action stemming from the PCSK9 cholesterol-drug patent wars (Praluent/Repatha), giving him a pharma/biotech fact pattern; his broader docket also spans software/platform antitrust (e.g., Epic Games v. Google).

Side preference & firm context. All tracked appearances are defendant-side (1 of 1), defending large operating companies — Amgen in the tracked case, plus Epic Games, Louis Dreyfus, Vivendi, and others — with no NPE/PAE prosecution work identified. He spent nearly 30 years as a Cravath, Swaine & Moore litigation partner and moved to Simpson Thacher & Bartlett as a New York litigation partner in July 2026 (Bloomberg Law).

Notable cases & PTAB. In the tracked case he led Amgen's defense of Regeneron's monopolization claims; a jury trial was held before Judge Jennifer L. Hall in May 2025, with post-trial JMOL briefing still pending as of mid-2026 (CourtListener). More prominent verified results: the unanimous jury verdict for Epic Games against Google (2023); the trial win defeating the DOJ's challenge to the Imperial Sugar sale, unanimously affirmed on appeal; and the consent order resolving the FTC's challenge to Amgen's $27.8B Horizon Therapeutics acquisition (Cravath bio). No evidence he appears regularly in IPR/PGR proceedings.

Bar / education. Admitted in New York (1999); LL.B. (Hons) and B.Com. from the University of Auckland (1994), M.ComLaw with First Class Honors (1997), and LL.M. from the University of Chicago Law School (1998) (Simpson Thacher bio; Super Lawyers).